PatientsVille.com Logo

HYPERHIDROSIS and Mirtazapine

PatientsVille

HYPERHIDROSIS Symptoms and Causes

Sweat is a clear, salty liquid produced by glands in your skin. Sweating is how your body cools itself. You sweat mainly under your arms and on your feet and palms. When sweat mixes with bacteria on your skin, it can cause a smell. Bathing regularly and using antiperspirants or deodorants can help control the odor.

Sweating a lot is normal when it is hot or when you exercise, are anxious, or have a fever. It also happens during menopause. If you often sweat too much, it's called Hyperhidrosis. Causes include thyroid or nervous system disorders, low blood sugar, or another health problem.

Sweating too little, anhidrosis, can be life-threatening because your body can overheat. Causes of anhidrosis include dehydration, burns, and some skin and nerve disorders.

Check out the latest treatments for HYPERHIDROSIS

HYPERHIDROSIS treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Does mirtazapine have muscles side effects?

Hi, I have been on mittazapine for 10 days, sleepy , tierd all the time and slugish in response to conversation just horrid feel gastly , head ace, The worst went to bed 11pm took the 15mg pill, went to the loo at 3am and collapse

I have experienced a mild form of hyperhidrosis since I was in middle school. Through highschool, I would tape paper towels under my arms, wear tanktops, put on an insane amount of deodorant and put baby powder on three times a day.&nbs

HYPERHIDROSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Botox (onabotulinumtoxinA);   Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB);   Drug: NaCl (placebo)
Outcome Measures: DLQI (Dermatology Life Quality Index);   AE (Adverse Events);   Gravimetry;   HDSS (Hyperhidrosis Disease Severity Scale);   Health outcome (EQ-5D);   LSAS-SR (Liebowitz Social Anxiety Scale-Self Report);   MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report);   Global Assessment of Therapy
2 Not yet recruiting Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Condition: Primary Hyperidrosis
Interventions: Drug: Oxybutynin;   Drug: Placebo
Outcome Measures: Oxybutynin Chloride efficacy;   Perception of improvement;   Evaluate therapeutic safety;   Quality of life;   Time of subject response;   Duration of response;   Evaluation between quality of life and groups
3 Recruiting Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Device: Ulthera System Treatment
Outcome Measures: Reduction in the number of sweat glands from baseline to 90-days post-treatment.;   Reduction in spontaneous axillary sweat production assessed by gravimetric method at 90-days post treatment;   HDSS score reduction;   Starch iodine test
4 Recruiting Tx Axillary Hyperhidrosis 1210nm Diode Laser
Condition: Axillary Hyperhidrosis
Intervention: Device: 1210nm Diode Laser treatments
Outcome Measures: subjective global assessment questionnaire;   gravimetric analysis;   modified starch-iodine test
5 Recruiting Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Dose 1 of DRM04B;   Drug: Dose 2 of DRM04B;   Drug: Dose 1 of DRM04;   Drug: Dose 2 of DRM04;   Other: Vehicle
Outcome Measures: Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4;   Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 6;   Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6
6 Recruiting A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Drug: BBI-4000
Outcome Measures: Percent change in the gravimetrically measured sweat production from baseline;   Absolute change in the gravimetrically measured sweat production from baseline;   Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.;   Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline
7 Recruiting Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
Condition: Hyperhidrosis
Intervention: Drug: [14C]Umeclidinium 18.5 mg
Outcome Measures: PK Assessment (Cmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (tmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (AUC) for [14C] umeclidinium and total radioactivity;   PK Assessment (t1/2) for [14C] umeclidinium and total radioactivity;   Compartmental modeling of absorption rate for [14C] umeclidinium;   Compartmental modeling of elimination rate for [14C] umeclidinium;   Determine the amount of Umeclidinium absorbed in the skin;   Safety Assessment for AEs;   Safety Assessment for ECGs, and telemetry;   Safety Assessment for hematology laboratory parameters;   Safety Assessment for measurement of blood pressure;   Number of subjects with application site skin irritation;   Safety Assessment for clinical chemistry laboratory parameters;   Safety Assessment for measurement of pulse rate
8 Recruiting Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
Conditions: Hyperhydrosis;   Depression
Intervention: Drug: Glycopyrrolate
Outcome Measures: Clinical Global Impression- Improvement scores;   change in mean of patient rated severity of sweating for each week, and change in mean skin conductance for each week
9 Recruiting Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Condition: Menopausal Hot Flushes
Intervention: Drug: Sage extract, 3400 mg , DER 1:17
Outcome Measures: Change from Baseline Hyperhidrosis Disease Severity Scale;   Change from Baseline Menopause Rating Scale / MRS;   Change from Baseline Modified Dem Tect
10 Recruiting Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle
Condition: Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc.
Intervention: Procedure: lumbar sympathetic ganglion block
Outcome Measures: temperature change;   muscle or vessel shadow
11 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
12 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
Outcome Measure:
13 Not yet recruiting Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
Condition: Complex Regional Pain Syndrome Type I of the Upper Limb
Intervention: Procedure: unilateral single-port VATS sympathicotomy
Outcome Measures: Change in perceived pain measured in Visual Analogue Scale;   Change in function in extremity